Last reviewed · How we verify

Rivastigmine transdermal patch — Competitive Intelligence Brief

Rivastigmine transdermal patch (Rivastigmine transdermal patch) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cholinesterase inhibitor. Area: Neurology.

marketed Cholinesterase inhibitor Acetylcholinesterase; Butyrylcholinesterase Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Rivastigmine transdermal patch (Rivastigmine transdermal patch) — Novartis. Rivastigmine is a cholinesterase inhibitor that increases acetylcholine levels in the brain by blocking the enzyme that breaks it down.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Rivastigmine transdermal patch TARGET Rivastigmine transdermal patch Novartis marketed Cholinesterase inhibitor Acetylcholinesterase; Butyrylcholinesterase
Bloxiverz NEOSTIGMINE Fresenius Kabi marketed Cholinesterase Inhibitor Acetylcholinesterase 2013-01-01
Razadyne GALANTAMINE Johnson & Johnson marketed Cholinesterase Inhibitor Acetylcholinesterase 2001-01-01
Aricept DONEPEZIL Eisai marketed Cholinesterase Inhibitor Sigma non-opioid intracellular receptor 1 1996-01-01
Ovide MALATHION Taro marketed Cholinesterase Inhibitor [EPC] Melatonin receptor type 1A 1982-01-01
Phospholine Iodide ECHOTHIOPHATE Fera Pharms Llc marketed Cholinesterase Inhibitor Acetylcholinesterase 1960-01-01
Mytelase AMBENONIUM Sanofi marketed Cholinesterase Inhibitor Acetylcholinesterase 1956-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cholinesterase inhibitor class)

  1. Novartis · 3 drugs in this class
  2. Eisai Co., Ltd. · 1 drug in this class
  3. Icure Pharmaceutical Inc. · 1 drug in this class
  4. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 drug in this class
  5. Merck Sharp & Dohme LLC · 1 drug in this class
  6. Pfizer · 1 drug in this class
  7. Pontificia Universidade Catolica de Sao Paulo · 1 drug in this class
  8. Singapore General Hospital · 1 drug in this class
  9. Sunnybrook Health Sciences Centre · 1 drug in this class
  10. Taipei Veterans General Hospital, Taiwan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rivastigmine transdermal patch — Competitive Intelligence Brief. https://druglandscape.com/ci/rivastigmine-transdermal-patch. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: